Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2010-01-12096,2010,Vanagas 2010 Medicina (Kaunas),110000,Peginterferon alfa-2a VERSUS Lamivudine for 5 years IN Patients with chronic hepatitis B in Lithuania,21532288,Patients with chronic hepatitis B in Lithuania,Peginterferon alfa-2a,"Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.",Lamivudine for 5 years,NE
2010-01-12096,2010,Vanagas 2010 Medicina (Kaunas),20000,Peginterferon alfa-2a VERSUS Lamivudine for 48 weeks IN Patients with chronic hepatitis B in Lithuania,21532288,Patients with chronic hepatitis B in Lithuania,Peginterferon alfa-2a,"Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.",Lamivudine for 48 weeks,NE
2010-01-11939,2010,Vanagas 2010 Medicina (Kaunas),59000,Six-month methadone maintenance treatment program VERSUS None IN All opioid-addicted persons visiting the outpatient methadone maintenance program for the first time in Lithuania,20571298,All opioid-addicted persons visiting the outpatient methadone maintenance program for the first time in Lithuania,Six-month methadone maintenance treatment program,Cost-utility analysis of methadone maintenance treatment in Lithuania.,None,NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
